A D Lázaro-Sánchez1, P Salces-Ortiz2, L I Velásquez3, D Orozco-Beltrán3, N Díaz-Fernández2, A Juárez-Marroquí2. 1. Medical Oncology Service of the University Hospital of Sant Joan d'Alacant, Ctra. Nnal. 332, s/n, 03550, Alicante, Spain. anlazaro@hotmail.com. 2. Medical Oncology Service of the University Hospital of Sant Joan d'Alacant, Ctra. Nnal. 332, s/n, 03550, Alicante, Spain. 3. Department of Clínical Medicine of the Miguel Hernández University of Elche, Alicante, Spain.
Abstract
INTRODUCTION: Recent medical investigations suggest that HLA-G, due to its tolerogenic properties, can be used as a biomarker in the diagnosis, treatment, and prognosis of different neoplasms. This observational prospective pilot study aims at detecting sHLA-G in the serum and saliva of patients diagnosed with colorectal cancer (CRC). For this purpose, we compared the expression of sHLA-G from patients with a control sample from a healthy population. MATERIALS AND METHODS: Using the specific enzyme-linked immunosorbent assay (ELISA) method, the expression of sHLA-G in the serum and saliva samples from patients affected by CRC (n = 20) and in a control sample (n = 10) were analyzed. RESULTS: The data showed that in patients with CRC, salivary sHLA-G values were significantly higher than in the control group (18.84 U/ml versus 6.3 U/ml, p = 0.036). In addition, higher levels of sHLA-G were observed in the saliva of patients with CRC in more advanced stages, compared with patients in early stages (24.2 U/ml vs. 8.1 U/ml, p = 0.019). A significant correlation was observed between the concentration of sHLA-G in the serum and saliva of the analyzed samples (Spearman correlation 0.7, p = 0.004). CONCLUSIONS: This study demonstrates, for the first time, the possibility of detecting sHLA-G in the saliva of patients with CRC, resulting in a less invasive alternative to venipuncture. Likewise, we propose that sHLA-G could be an attractive molecular target based on its significant high levels in advanced stages.
INTRODUCTION: Recent medical investigations suggest that HLA-G, due to its tolerogenic properties, can be used as a biomarker in the diagnosis, treatment, and prognosis of different neoplasms. This observational prospective pilot study aims at detecting sHLA-G in the serum and saliva of patients diagnosed with colorectal cancer (CRC). For this purpose, we compared the expression of sHLA-G from patients with a control sample from a healthy population. MATERIALS AND METHODS: Using the specific enzyme-linked immunosorbent assay (ELISA) method, the expression of sHLA-G in the serum and saliva samples from patients affected by CRC (n = 20) and in a control sample (n = 10) were analyzed. RESULTS: The data showed that in patients with CRC, salivary sHLA-G values were significantly higher than in the control group (18.84 U/ml versus 6.3 U/ml, p = 0.036). In addition, higher levels of sHLA-G were observed in the saliva of patients with CRC in more advanced stages, compared with patients in early stages (24.2 U/ml vs. 8.1 U/ml, p = 0.019). A significant correlation was observed between the concentration of sHLA-G in the serum and saliva of the analyzed samples (Spearman correlation 0.7, p = 0.004). CONCLUSIONS: This study demonstrates, for the first time, the possibility of detecting sHLA-G in the saliva of patients with CRC, resulting in a less invasive alternative to venipuncture. Likewise, we propose that sHLA-G could be an attractive molecular target based on its significant high levels in advanced stages.
Entities:
Keywords:
Colorectal cancer biomarker; ELISA; Non-invasive sampling; sHLA-G
Authors: Maria Bucova; Kristina Kluckova; Jan Kozak; Boris Rychly; Magda Suchankova; Marian Svajdler; Viktor Matejcik; Juraj Steno; Eszter Zsemlye; Vladimira Durmanova Journal: Diagnostics (Basel) Date: 2022-04-27
Authors: Christian Vaquero-Yuste; Ignacio Juarez; Marta Molina-Alejandre; Elisa María Molanes-López; Adrián López-Nares; Fabio Suárez-Trujillo; Alberto Gutiérrez-Calvo; Adela López-García; Inmaculada Lasa; Remedios Gómez; Eduardo Fernández-Cruz; Carmen Rodrígez-Sainz; Antonio Arnaiz-Villena; José Manuel Martín-Villa Journal: Front Immunol Date: 2021-09-07 Impact factor: 7.561
Authors: José Manuel Martín-Villa; Christian Vaquero-Yuste; Marta Molina-Alejandre; Ignacio Juarez; Fabio Suárez-Trujillo; Adrián López-Nares; José Palacio-Gruber; Luis Barrera-Gutiérrez; Eduardo Fernández-Cruz; Carmen Rodríguez-Sainz; Antonio Arnaiz-Villena Journal: Front Immunol Date: 2022-01-27 Impact factor: 7.561
Authors: Karolina Piekarska; Paweł Radwan; Agnieszka Tarnowska; Andrzej Wiśniewski; Rafał Krasiński; Michał Radwan; Jacek R Wilczyński; Andrzej Malinowski; Izabela Nowak Journal: Front Immunol Date: 2022-01-17 Impact factor: 7.561